citric acid, anhydrous has been researched along with Cardiovascular Stroke in 10 studies
Citric Acid: A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.
citric acid : A tricarboxylic acid that is propane-1,2,3-tricarboxylic acid bearing a hydroxy substituent at position 2. It is an important metabolite in the pathway of all aerobic organisms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We randomized 70 acute coronary syndrome patients undergoing percutaneous coronary intervention to receive abciximab, eptifibatide, or tirofiban at doses used in the Evaluation of Platelet IIb/IIIa Inhibitor for STENTing (EPISTENT), Platelet glycoprotein IIb/IIIa in Unstable angina Receptor Suppression Using Integrilin Therapy (PURSUIT), and Platelet Receptor Inhibition in ischemic Syndrome Management in Patients Limited by Unstable Signs and symptoms (PRISM-PLUS)/Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis (RESTORE) trials, respectively." | 9.10 | Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, an ( Batchelor, WB; Califf, RM; Cantor, WJ; Davidian, M; DiBattiste, PM; Dillard, P; Gretler, D; Harrington, RA; Huang, Y; Larsen, RL; Mantell, RM; Ohman, EM; Sketch, MH; Tcheng, JE; Tolleson, TR; Zhang, D; Zidar, JP, 2002) |
| "Plasma levels of glutamate, alanine, free fatty acids (FFA), citrate, glucose, insulin, lactate, creatine kinase and aspartate aminotransferase were determined frequently during the first 2-48 h after onset of chest pain in 10 patients who developed acute myocardial infarction (AMI) and in 8 who did not (non-AMI)." | 7.67 | Altered plasma concentrations of glutamate, alanine and citrate in the early phase of acute myocardial infarction in man. ( Falstie-Jensen, N; Henningsen, P; Mortensen, PT; Nielsen, TT; Thomassen, AR; Thygesen, K, 1986) |
| "We randomized 70 acute coronary syndrome patients undergoing percutaneous coronary intervention to receive abciximab, eptifibatide, or tirofiban at doses used in the Evaluation of Platelet IIb/IIIa Inhibitor for STENTing (EPISTENT), Platelet glycoprotein IIb/IIIa in Unstable angina Receptor Suppression Using Integrilin Therapy (PURSUIT), and Platelet Receptor Inhibition in ischemic Syndrome Management in Patients Limited by Unstable Signs and symptoms (PRISM-PLUS)/Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis (RESTORE) trials, respectively." | 5.10 | Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, an ( Batchelor, WB; Califf, RM; Cantor, WJ; Davidian, M; DiBattiste, PM; Dillard, P; Gretler, D; Harrington, RA; Huang, Y; Larsen, RL; Mantell, RM; Ohman, EM; Sketch, MH; Tcheng, JE; Tolleson, TR; Zhang, D; Zidar, JP, 2002) |
| "Plasma levels of glutamate, alanine, free fatty acids (FFA), citrate, glucose, insulin, lactate, creatine kinase and aspartate aminotransferase were determined frequently during the first 2-48 h after onset of chest pain in 10 patients who developed acute myocardial infarction (AMI) and in 8 who did not (non-AMI)." | 3.67 | Altered plasma concentrations of glutamate, alanine and citrate in the early phase of acute myocardial infarction in man. ( Falstie-Jensen, N; Henningsen, P; Mortensen, PT; Nielsen, TT; Thomassen, AR; Thygesen, K, 1986) |
| "The notification of serious adverse events occurring resulting from the collection of blood or blood components is a statutory requirement." | 2.46 | [Serious adverse effects of blood collection]. ( Danic, B; Lefort, C, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (40.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yuan, Z | 1 |
| Tsou, YH | 1 |
| Zhang, XQ | 1 |
| Huang, S | 1 |
| Yang, Y | 1 |
| Gao, M | 1 |
| Ho, W | 1 |
| Zhao, Q | 1 |
| Ye, X | 1 |
| Xu, X | 1 |
| Dodd, MS | 1 |
| Atherton, HJ | 1 |
| Carr, CA | 1 |
| Stuckey, DJ | 1 |
| West, JA | 1 |
| Griffin, JL | 1 |
| Radda, GK | 1 |
| Clarke, K | 1 |
| Heather, LC | 1 |
| Tyler, DJ | 1 |
| Danic, B | 1 |
| Lefort, C | 1 |
| Hasan, AG | 1 |
| Brown, WR | 1 |
| Batchelor, WB | 1 |
| Tolleson, TR | 1 |
| Huang, Y | 1 |
| Larsen, RL | 1 |
| Mantell, RM | 1 |
| Dillard, P | 1 |
| Davidian, M | 1 |
| Zhang, D | 1 |
| Cantor, WJ | 1 |
| Sketch, MH | 1 |
| Ohman, EM | 1 |
| Zidar, JP | 1 |
| Gretler, D | 1 |
| DiBattiste, PM | 1 |
| Tcheng, JE | 1 |
| Califf, RM | 1 |
| Harrington, RA | 1 |
| HOELSCHER, B | 1 |
| Davis, WP | 1 |
| Graham, P | 1 |
| Stump, DC | 1 |
| Topol, EJ | 1 |
| Chen, AB | 1 |
| Hopkins, A | 1 |
| Collen, D | 1 |
| Thomassen, AR | 1 |
| Mortensen, PT | 1 |
| Nielsen, TT | 1 |
| Falstie-Jensen, N | 1 |
| Thygesen, K | 1 |
| Henningsen, P | 1 |
| Hwang, MH | 1 |
| Murdock, DK | 1 |
| Piao, ZE | 1 |
| Gries, WJ | 1 |
| Scanlon, PJ | 1 |
1 review available for citric acid, anhydrous and Cardiovascular Stroke
| Article | Year |
|---|---|
[Serious adverse effects of blood collection].
Topics: Anticoagulants; Arteries; Blood Component Removal; Blood Donors; Citric Acid; Hematoma; Humans; Inci | 2010 |
1 trial available for citric acid, anhydrous and Cardiovascular Stroke
| Article | Year |
|---|---|
Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, an
Topics: Abciximab; Acute Disease; Aged; Amino Acid Chloromethyl Ketones; Angina, Unstable; Angioplasty, Ball | 2002 |
8 other studies available for citric acid, anhydrous and Cardiovascular Stroke
| Article | Year |
|---|---|
Injectable Citrate-Based Hydrogel as an Angiogenic Biomaterial Improves Cardiac Repair after Myocardial Infarction.
Topics: Animals; Biocompatible Materials; Cell Adhesion; Cell Proliferation; Citric Acid; Disease Models, An | 2019 |
Impaired in vivo mitochondrial Krebs cycle activity after myocardial infarction assessed using hyperpolarized magnetic resonance spectroscopy.
Topics: Acetylcarnitine; Animals; Biomarkers; Citric Acid; Citric Acid Cycle; Disease Models, Animal; Female | 2014 |
Colonic cleansing for colonoscopy: a risk to be taken seriously.
Topics: Accidental Falls; Aged; Bradycardia; Cathartics; Chest Pain; Citric Acid; Colonoscopy; Dyspnea; Fata | 2011 |
[RECOVERY TIME AND THE MECHANISM OF ACTION OF ISCHEMIC AND CITRATE HEART ARREST].
Topics: Adenine Nucleotides; Animals; Cardiac Surgical Procedures; Citrates; Citric Acid; Coenzymes; Dogs; E | 1963 |
The effect of hypotonicity on the mean platelet volume of patients with thrombo-embolism.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Platelets; Cell Membrane; Cell Siz | 1992 |
Monitoring of hemostasis parameters during coronary thrombolysis with recombinant tissue-type plasminogen activator.
Topics: Amino Acid Chloromethyl Ketones; Aprotinin; Blood Specimen Collection; Citrates; Citric Acid; Fibrin | 1988 |
Altered plasma concentrations of glutamate, alanine and citrate in the early phase of acute myocardial infarction in man.
Topics: Aged; Alanine; Blood Glucose; Citrates; Citric Acid; Digoxin; Fatty Acids, Nonesterified; Glutamates | 1986 |
Differential hemodynamic effects of Hypaque-76 and Renografin-76 during coronary angiography: the role of calcium-binding additives.
Topics: Animals; Blood Pressure; Calcium; Citrates; Citric Acid; Contrast Media; Coronary Angiography; Diatr | 1988 |